Accelerated Immunosenescence and Chronic Kidney Disease
- Conditions
- Renal Failure
- Interventions
- Biological: Blood sample
- Registration Number
- NCT02116270
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Brief Summary
The aim of this study is to investigate the impact of renal function and dialysis techniques on the percentage of senescent T lymphocytes.
- Detailed Description
The immunosenescence is a complex and profound remodeling of the immune system during life. It is mainly due to thymic involution and repeated antigenic stimulation. Kidney disease is associated with a decrease in adaptive immunity as evidenced by the decrease in vaccine response and increased susceptibility to infections, similar to those observed in the elderly population.
However, data on aging of the immune system in chronic kidney disease remains incomplete. Furthermore, the determinants of immunosenescence are not also not known. It is possible that "uremic" factors help explain the phenotypic and functional changes of lymphocytes, as antigenic stimuli associated with repeated bio-compatible materials used in dialysis contact.
The purpose of this study is to describe the phenotypes of the immune system of renal and analyze the determinants of these changes.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 222
- Patient able to understand the reason of the study
- Patient not opposed to the conservation of biological samples for scientific research
- Patient suffering from psychotic illness
- Any history of immunosuppressive therapy (except steroids up to 5mg/day)
- History of cancer (except skin cancer) or treated hematological malignancy
- Infectious episode required hospitalization not older 3 months
- Hepatitis B or C infection
- HIV infection, active or inactive
- For dialysis patients: renal failure on dialysis for less than 3 months and/or have benefited from two techniques for renal replacement therapy in the last 6 months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control group Blood sample Patients in this group control (normal renal function) are followed in the urology department. A blood sample is performed on the day of inclusion. Severe renal failure Blood sample Patients in this group suffer from renal failure stage 4 and are not under dialysis. A blood sample is performed on the day of inclusion. Hemodialysis Blood sample Patient with renal failure, under hemodialysis for at least 3 months. A blood sample is performed on the day of inclusion. Peritoneal dialysis Blood sample Patients with renal failure, under peritoneal dialysis for at least 3 months. A blood sample is performed on the day of inclusion.
- Primary Outcome Measures
Name Time Method Percentage of Cluster of Differentiation (CD) 4/8+ CD 57+ CD 28- lymphocytes (senescent lymphocytes) 6 months The primary outcome measure is the percentage of CD 4/8+ CD 57+ CD 28- lymphocytes by flow cytometry. The technique used is a 6 colors surface labelling of T lymphocytes to study the T cell senescent population.
- Secondary Outcome Measures
Name Time Method Level of phospho-histone 2AX (gH2AX) in peripheral blood T lymphocytes 6 months This level is obtained by flow cytometry after permeabilization and labelling of Peripheral Blood Mononuclear Cells (PBMC).
T-cell receptor excision circle (TREC) level in PBMC. 6 months TRECs study is based on a technique of quantitative PCR using DNA extracted from PBMC.
Telomerase Activity of T lymphocytes 6 months The telomerase activity of T lymphocytes is assessed by a method of Polymerase chain reaction (PCR)-ELISA.
Telomere length in T lymphocytes 6 months Study of telomere length is performed after extraction of DNA from isolated T cells. The length is determined by a quantitative PCR technique relative to a reference gene.
Proportion of Recent Thymic Emigrants (RTE) in peripheral blood T lymphocytes 6 months RTE T cells will be defined by flow cytometry, according to co-expression of CD 4, CD 8,CD 31 and CD 45RA
Trial Locations
- Locations (1)
Service de néphrologie, CHU de Besançon
🇫🇷Besançon, France